Previous close | 6.50 |
Open | 9.65 |
Bid | 9.40 |
Ask | 9.95 |
Strike | 22.50 |
Expiry date | 2025-01-17 |
Day's range | 9.40 - 9.65 |
Contract range | N/A |
Volume | |
Open interest | 61 |
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Key Insights Institutions' substantial holdings in Novavax implies that they have significant influence over the...